Biohaven Non Current Assets Total from 2010 to 2024
| BHVN Stock | USD 38.45 1.37 3.69% |
Non Current Assets Total | First Reported 2017-03-31 | Previous Quarter 70.8 M | Current Value 69.8 M | Quarterly Volatility 54.1 M |
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven main balance sheet or income statement drivers, such as Selling General Administrative of 60.1 M, Other Operating Expenses of 399.6 M or Research Development of 315.7 M, as well as many exotic indicators such as Price To Sales Ratio of 8.54, Dividend Yield of 0.0 or PTB Ratio of 7.48. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
Biohaven | Non Current Assets Total |
Latest Biohaven Pharmaceutical's Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Biohaven Pharmaceutical Holding over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Biohaven Pharmaceutical's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biohaven Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Biohaven Non Current Assets Total Regression Statistics
| Arithmetic Mean | 24,707,610 | |
| Geometric Mean | 18,118,061 | |
| Coefficient Of Variation | 91.82 | |
| Mean Deviation | 17,946,762 | |
| Median | 10,223,000 | |
| Standard Deviation | 22,686,566 | |
| Sample Variance | 514.7T | |
| Range | 64.6M | |
| R-Value | 0.77 | |
| Mean Square Error | 221.5T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 3,930,472 | |
| Total Sum of Squares | 7205.5T |
Biohaven Non Current Assets Total History
About Biohaven Pharmaceutical Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Biohaven Pharmaceutical income statement, its balance sheet, and the statement of cash flows. Biohaven Pharmaceutical investors use historical funamental indicators, such as Biohaven Pharmaceutical's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Biohaven Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Biohaven Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biohaven Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Biohaven Pharmaceutical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Biohaven Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 70.8 M | 40.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Biohaven Pharmaceutical Correlation against competitors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Biohaven Stock analysis
When running Biohaven Pharmaceutical's price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Biohaven Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.90) | Return On Assets (0.65) | Return On Equity (1.34) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.